Arbutus Biopharma Corp Fair Value Assumptions, Expected Volatility Rate (Deprecated 2018-01-31)
Arbutus Biopharma Corp (ABUS) reported Fair Value Assumptions, Expected Volatility Rate (Deprecated 2018-01-31) of 41.95% for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-22.
Discontinued › Notes › Fair Value Measures and Disclosures
us-gaap:FairValueAssumptionsExpectedVolatilityRate · last filed 2017-03-22
- Arbutus Biopharma Corp fair value assumptions, expected volatility rate (deprecated 2018-01-31) for the quarter ending 2016-03-31 was 67.25%, a 31.85% decline year-over-year.
- Arbutus Biopharma Corp fair value assumptions, expected volatility rate (deprecated 2018-01-31) for the quarter ending 2015-03-31 was 98.68%, a 49.15% increase year-over-year.
- Arbutus Biopharma Corp fair value assumptions, expected volatility rate (deprecated 2018-01-31) for the quarter ending 2014-03-31 was 66.16%.
- Arbutus Biopharma Corp fair value assumptions, expected volatility rate (deprecated 2018-01-31) for the quarter ending 2013-12-31 was 47.03%.
- Arbutus Biopharma Corp fair value assumptions, expected volatility rate (deprecated 2018-01-31) for fiscal 2016 was 41.95%, a 14.51% decline from fiscal 2015.
- Arbutus Biopharma Corp fair value assumptions, expected volatility rate (deprecated 2018-01-31) for fiscal 2015 was 49.07%, a 42.42% decline from fiscal 2014.
- Arbutus Biopharma Corp fair value assumptions, expected volatility rate (deprecated 2018-01-31) for fiscal 2014 was 85.22%, a 81.20% increase from fiscal 2013.
- Arbutus Biopharma Corp fair value assumptions, expected volatility rate (deprecated 2018-01-31) for fiscal 2013 was 47.03%, a 17.57% increase from fiscal 2012.
| Period end | Fair Value Assumptions, Expected Volatility Rate (Deprecated 2018-01-31) | Fair Value Assumptions, Expected Volatility Rate (Deprecated 2018-01-31) 0 month | Fair Value Assumptions, Expected Volatility Rate (Deprecated 2018-01-31) 1 month | Fair Value Assumptions, Expected Volatility Rate (Deprecated 2018-01-31) 3 month | Fair Value Assumptions, Expected Volatility Rate (Deprecated 2018-01-31) 6 month | Fair Value Assumptions, Expected Volatility Rate (Deprecated 2018-01-31) 9 month | Fair Value Assumptions, Expected Volatility Rate (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|---|---|---|
| 2016-12-31 | 41.95% 10-K · filed 2017-03-22 | ||||||
| 2016-09-30 | 49.69% 10-Q · filed 2016-11-03 | ||||||
| 2016-06-30 | 67.37% 10-Q · filed 2016-08-04 | ||||||
| 2016-03-31 | 67.25% 10-Q · filed 2016-05-04 | ||||||
| 2015-12-31 | 49.07% 10-K · filed 2017-03-22 | ||||||
| 2015-09-30 | 65.43% 10-Q · filed 2015-11-05 | ||||||
| 2015-06-30 | 69.32% 10-Q · filed 2015-08-07 | ||||||
| 2015-03-31 | 98.68% 10-Q · filed 2015-05-06 | ||||||
| 2014-12-31 | 85.22% 10-K · filed 2016-03-09 | ||||||
| 2014-09-30 | 115.31% 10-Q · filed 2014-11-07 | ||||||
| 2014-06-30 | 96.17% 10-Q · filed 2014-08-14 | ||||||
| 2014-03-31 | 66.16% 10-Q · filed 2014-05-14 | ||||||
| 2013-12-31 | 47.03% 10-Q · filed 2014-05-14 | 47.03% 10-K · filed 2015-03-13 | |||||
| 2012-12-31 | 40.00% 10-K · filed 2014-03-28 | ||||||
| 2012-02-29 | 40.00% 10-K · filed 2015-03-13 | 40.00% 10-K · filed 2014-03-28 | |||||
| 2011-12-31 | 40.00% 20-F · filed 2013-03-27 | ||||||
| 2011-06-16 | 40.00% 10-K · filed 2014-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |